Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has granted 37,000 restricted stock units to three newly hired employees. The Compensation Committee approved these awards under the company's 2022 Inducement Plan, with a grant date of September 3, 2024. This action complies with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for new employees joining Arcutis.
The restricted stock units have a four-year vesting schedule, with 25% vesting on each annual anniversary of the vesting commencement date. Vesting is contingent upon continuous employment with Arcutis. This disclosure aligns with Nasdaq Listing Rule 5635(c)(4) requirements.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata nelle innovazioni in campo immuno-dermatologico, ha concesso 37.000 unità azionarie riservate a tre nuovi dipendenti assunti. Il Comitato per la Compensazione ha approvato questi premi nell'ambito del Piano di Induzione 2022 dell'azienda, con una data di concessione del 3 settembre 2024. Questa azione è conforme alla Regola di Quotazione 5635(c)(4) di Nasdaq, fungendo da incentivo per i nuovi dipendenti che si uniscono ad Arcutis.
Le unità azionarie riservate hanno un programma di maturazione di quattro anni, con il 25% che matura ogni anno alla data di anniversario dell'inizio della maturazione. La maturazione è subordinata a un'occupazione continua in Arcutis. Questa divulgazione è in linea con i requisiti della Regola di Quotazione 5635(c)(4) di Nasdaq.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial que se especializa en innovaciones en inmuno-dermatología, ha otorgado 37,000 unidades de acciones restringidas a tres empleados recién contratados. El Comité de Compensación aprobó estas asignaciones bajo el Plan de Inducción 2022 de la compañía, con una fecha de concesión del 3 de septiembre de 2024. Esta acción cumple con la Regla de Listado 5635(c)(4) de Nasdaq, sirviendo como un incentivo para los nuevos empleados que se unen a Arcutis.
Las unidades de acciones restringidas tienen un cronograma de adquisición de cuatro años, con el 25% adquiriéndose en cada aniversario anual de la fecha de inicio de adquisición. La adquisición depende de la continuidad del empleo en Arcutis. Esta divulgación está alineada con los requisitos de la Regla de Listado 5635(c)(4) de Nasdaq.
Arcutis Biotherapeutics (Nasdaq: ARQT), 면역 피부 치료 혁신에 특화된 상업 단계의 생물약품 회사가 세 명의 신규 직원에게 37,000개의 제한 주식 단위를 부여했습니다. 보상 위원회는 회사의 2022 유도 계획에 따라 이 상을 승인했으며, 부여일은 2024년 9월 3일입니다. 이 조치는 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 직원이 Arcutis에 합류하도록 유도하는 역할을 합니다.
제한 주식 단위는 4년의 베스팅 일정을 가지고 있으며, 매년 베스팅 시작일의 기념일에 25%가 베스트됩니다. 베스팅은 Arcutis에서의 지속적인 고용에 따라 달라집니다. 이 공시는 Nasdaq 상장 규칙 5635(c)(4)의 요구사항에 부합합니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immunodermatologie, a accordé 37 000 unités d'actions restreintes à trois nouveaux employés. Le Comité de Rémunération a approuvé ces attributions dans le cadre du Plan d'Induction 2022 de l'entreprise, avec une date d'attribution du 3 septembre 2024. Cette action est conforme à la Règle de Cotation 5635(c)(4) de Nasdaq, agissant comme un incitatif pour les nouveaux employés rejoignant Arcutis.
Les unités d'actions restreintes ont un calendrier d'acquisition de quatre ans, avec 25 % qui acquièrent chaque année à l'anniversaire du début de l'acquisition. L'acquisition dépend d'un emploi continu chez Arcutis. Cette divulgation est en accord avec les exigences de la Règle de Cotation 5635(c)(4) de Nasdaq.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein Unternehmen der biopharmazeutischen Industrie in der kommerziellen Phase, das sich auf Innovationen in der Immundermatologie spezialisiert hat, hat 37.000 eingeschränkte Aktienoptionen an drei neu eingestellte Mitarbeiter vergeben. Der Vergütungsausschuss genehmigte diese Auszeichnungen im Rahmen des Unternehmensplans zur Anwerbung von 2022, mit einem Zuweisungsdatum vom 3. September 2024. Diese Maßnahme erfüllt die Nasdaq-Notierungsregel 5635(c)(4) und dient als Anreiz für neue Mitarbeiter, die zu Arcutis stoßen.
Die eingeschränkten Aktienoptionen unterliegen einem Vesting-Zeitplan von vier Jahren, wobei 25% an jedem Jahrestag des Vesting-Beginns fällig werden. Das Vesting ist an eine kontinuierliche Beschäftigung bei Arcutis gebunden. Diese Offenlegung entspricht den Anforderungen der Nasdaq-Notierungsregel 5635(c)(4).
- Arcutis is attracting new talent with stock-based compensation
- The company is complying with Nasdaq listing rules, demonstrating good corporate governance
- Potential dilution of existing shareholders' equity due to new stock grants
WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 37,000 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 3, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant to new employees?
What is the vesting schedule for the restricted stock units granted by Arcutis (ARQT)?
Under which plan were the Arcutis Biotherapeutics (ARQT) stock grants made?
What is the grant date for the restricted stock units issued by Arcutis (ARQT)?
